Eltrombopag for the treatment of immune thrombocytopenia.

Abstract:

:Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count that has persisted for more than 12 months. Patients with severe, symptomatic disease may have significant morbidity and require treatment. Historically, the underlying cause of ITP was believed to be accelerated platelet destruction by antiplatelet antibodies. Treatment options were therefore focused on reducing platelet autoantibody production or inhibiting macrophage-mediated platelet destruction. These treatments are not always effective or, at best, only have a transient effect and treatment-related adverse events often preclude their long-term use. Recently, impaired platelet production was observed in many ITP patients. Therefore, growth factor or growth factor analogs that stimulate megakaryopoiesis may be useful in ITP treatment. This article presents data on the pharmacology, clinical efficacy, safety profile and future roles of eltrombopag, an orally bioavailable, low-molecular-weight, synthetic nonpeptide thrombopoietin receptor agonist, in the treatment of ITP.

journal_name

Expert Rev Hematol

authors

Cheng G

doi

10.1586/ehm.11.25

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

261-9

issue

3

eissn

1747-4086

issn

1747-4094

journal_volume

4

pub_type

杂志文章
  • Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.

    abstract::Indolent non-Hodgkin's lymphoma (iNHL) describes a group of B-cell lymphomas with a long median survival and a relapsing-remitting clinical course. Although existing treatments are initially effective, patients often relapse, demonstrating decreasing efficacy with successive treatment courses. Alternative treatments a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.1071663

    authors: Davies A

    更新日期:2015-10-01 00:00:00

  • Ponatinib in the therapy of chronic myeloid leukemia.

    abstract:INTRODUCTION:Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder that has become the neoplastic poster child for understanding the disease biology of a malignant disease and targeting effective therapy. The targeted therapy of BCR-ABL inhibition by tyrosine kinase inhibitors (TKI) has provided the epitome f...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1232163

    authors: Poch Martell M,Sibai H,Deotare U,Lipton JH

    更新日期:2016-10-01 00:00:00

  • What does the 'Cochrane database of systematic reviews' tell us about hemophilia?

    abstract::Introduction: The purpose of this article is to review which data about hemophilia are currently provided by the Cochrane database of systematic reviews (CDBSR). Methodological consideration: All statements about hemophilia in the Cochrane Collaboration are based on evidence generated in randomized controlled clinical...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1676718

    authors: Rodriguez-Merchan EC

    更新日期:2019-11-01 00:00:00

  • Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.

    abstract::Thromboembolic diseases require anticoagulation for their prevention and treatment. New oral anticoagulants, specifically direct factor Xa and thrombin inhibitors, were developed to overcome the limitations of conventional anticoagulants. Their benefit has been demonstrated using fixed doses without laboratory-guided ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.79

    authors: Harenberg J,Marx S,Erdle S,Krämer R

    更新日期:2012-02-01 00:00:00

  • Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches.

    abstract::Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good,...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.10.73

    authors: Tanosaki R,Tobinai K

    更新日期:2010-12-01 00:00:00

  • Transfusion strategies in patients undergoing stem-cell transplantation.

    abstract::Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause diff...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.14

    authors: Radia R,Pamphilon D

    更新日期:2011-04-01 00:00:00

  • The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

    abstract:INTRODUCTION:Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. As a result, there is widespread variation in the interpretation and implementation of these guidelines. Areas covered: This review will cover: th...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1437345

    authors: Cavo M,Terpos E,Bargay J,Einsele H,Cavet J,Greil R,de Wit E

    更新日期:2018-03-01 00:00:00

  • Factor VIII therapy for hemophilia A: current and future issues.

    abstract::Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic u...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.899896

    authors: Aledort L,Ljung R,Mann K,Pipe S

    更新日期:2014-06-01 00:00:00

  • Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.

    abstract:INTRODUCTION:Pulmonary hypertension (PH) develops in a significant number of patients with sickle cell disease (SCD), resulting in increased morbidity and mortality. This review focuses on PH pathophysiology, risk stratification, and new recommendations for screening and treatment for patients with SCD. Areas covered: ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2017.1364989

    authors: Shilo NR,Morris CR

    更新日期:2017-10-01 00:00:00

  • Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?

    abstract:INTRODUCTION:First and second generation tyrosine kinase inhibitors, represent a new, fully biologic and targeted approach to chronic lymphocytic leukemia and allowed to obtain high responses and acceptable tolerability even in elderly and high risk patients. On the other hand, prolonged experience with these agents ha...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1191943

    authors: Frustaci AM,Montillo M,Picardi P,Mazzucchelli M,Cairoli R,Tedeschi A

    更新日期:2016-07-01 00:00:00

  • Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.

    abstract::Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newe...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.963048

    authors: Robak T

    更新日期:2014-12-01 00:00:00

  • Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.

    abstract::Recombinant IFN-α (rIFN-α) induces complete hematologic remissions in patients with myeloproliferative neoplasms (MPNs), but its use has been limited by side effects owing to the relatively high doses used. Now, low-dose rIFN-α is stressed, starting relatively early in the course of the MPNs. In polycythemia vera, thi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.12.69

    authors: Silver RT,Kiladjian JJ,Hasselbalch HC

    更新日期:2013-02-01 00:00:00

  • Prognostic tools in follicular lymphomas.

    abstract::Despite significant improvements in treatment modalities over the 10 years, the clinical course of patients with follicular lymphoma (FL) remains heterogeneous. Thus, prognostic indexes are still required to direct treatment choices and for the design of clinical trials. Investigators have conducted a variety of studi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.34

    authors: Luminari S,Cox MC,Montanini A,Federico M

    更新日期:2009-10-01 00:00:00

  • Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the t...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1270203

    authors: Tees MT,Flinn IW

    更新日期:2017-02-01 00:00:00

  • Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?

    abstract::Major advances have significantly improved the outcome of mantle cell lymphoma (MCL). Incorporation of rituximab to CHOP regimen, the adoption of high dose cytarabine with frontline autologous stem cell transplantation in young patients, maintenance rituximab or bortezomib based chemotherapy in elderly patients, impro...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1134309

    authors: El Halabi L,Ghez D,Ribrag V

    更新日期:2016-03-01 00:00:00

  • Double hit lymphoma: from biology to therapeutic implications.

    abstract:INTRODUCTION:Diffuse large B-cell lymphoma (DLBCL) is a molecularly heterogeneous disease defined by different cellular origins and mechanisms of oncogenic activation. Approximately 10% of DLBCL cases harbor a MYC rearrangement and this has been associated with a more aggressive clinical course following standard thera...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1182858

    authors: Burotto M,Berkovits A,Dunleavy K

    更新日期:2016-07-01 00:00:00

  • Mobilization of hematopoietic stem cells into the peripheral blood.

    abstract::Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy. Methods to improve mobilization efficiency and yields are rapidly emerging. Traditional methods include chemotherapy with or without myeloid growth factors. Plerixafor, a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.54

    authors: Damon LE,Damon LE

    更新日期:2009-12-01 00:00:00

  • An update on biology, diagnosis and treatment of primary plasma cell leukemia.

    abstract:INTRODUCTION:Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendati...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1598258

    authors: Musto P,Statuto T,Valvano L,Grieco V,Nozza F,Vona G,Bochicchio GB,La Rocca F,D'Auria F

    更新日期:2019-04-01 00:00:00

  • T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?

    abstract::Introduction: Severe sickle cell disease is associated with progressive end-organ damage and early mortality in adults. While allogeneic hematopoietic cell transplant from a matched related donor is curative, the vast majority of patients do not have a compatible sibling. Accordingly, platforms using haploidentical do...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1642103

    authors: Patel DA,Akinsete AM,Connelly JA,Kassim AA

    更新日期:2019-09-01 00:00:00

  • Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.

    abstract::β-thalassemias are caused by nearly 300 mutations of the β-globin gene, leading to a low or absent production of adult hemoglobin (HbA). Two major therapeutic approaches have recently been proposed: gene therapy and induction of fetal hemoglobin (HbF) with the objective of achieving clinically relevant levels of Hbs. ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.13.24

    authors: Breda L,Rivella S,Zuccato C,Gambari R

    更新日期:2013-06-01 00:00:00

  • Andexanet alfa for the treatment of hemorrhage.

    abstract:INTRODUCTION:While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1532287

    authors: Cervi A,Crowther M

    更新日期:2018-11-01 00:00:00

  • Lestaurtinib: a multi-targeted FLT3 inhibitor.

    abstract::Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for th...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2.1.17

    authors: Fathi AT,Levis M

    更新日期:2009-02-01 00:00:00

  • Sickle cell disease as a vascular disorder.

    abstract:INTRODUCTION:In sickle cell disease (SCD), hemoglobin S (HbS) red blood cells (RBCs) are characteristically deformed and inflexible. Often breaking down in the circulation, they exhibit increased adhesive properties with the endothelium and activated neutrophils and platelets, increasing the risk of occlusion of the mi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1758555

    authors: Ofori-Acquah SF

    更新日期:2020-06-01 00:00:00

  • A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.

    abstract:INTRODUCTION:Myeloproliferative neoplasms (MPNs) are associated with a variety of symptoms and signs which cause major morbidity for the patients. The disorders are associated with increased incidence of thromboembolic and hemorrhagic events which can lead to complications and shortened life expectancy. Areas covered: ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1410433

    authors: Greenfield G,McMullin MF

    更新日期:2018-01-01 00:00:00

  • Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

    abstract::Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.932687

    authors: Al-Hussaini M,DiPersio JF

    更新日期:2014-08-01 00:00:00

  • CD43 in the malignant flow cytometry laboratory in 2020.

    abstract::Objectives: CD43 can be useful in routine flow cytometry. We conducted a systematic review aiming to describe when CD43 is used by flow cytometry in malignant hematology and to determine its value in these settings. Methods: Systematic review of MEDLINE (search 'CD43' AND 'flow cytometry,' starting in 2010). Results: ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2021.1856653

    authors: Sorigue M

    更新日期:2021-01-01 00:00:00

  • Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.

    abstract::Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukem...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1144469

    authors: Hou HA,Tien HF

    更新日期:2016-05-01 00:00:00

  • An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.

    abstract::Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, consumption thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, the specific von Willebrand factor (VWF)-cl...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1611423

    authors: Joly BS,Coppo P,Veyradier A

    更新日期:2019-06-01 00:00:00

  • The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.

    abstract::Venous thromboembolism is a common cause of morbidity and mortality among patients undergoing elective orthopedic surgery. Due to the high incidence of venous thromboembolism in this setting, perioperative anticoagulation is the recommended approach for thromboprophylaxis. Low molecular weight heparin (LMWH), fondapar...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2013.853430

    authors: Rachidi S,Aldin ES,Greenberg C,Sachs B,Streiff M,Zeidan AM

    更新日期:2013-12-01 00:00:00

  • Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.

    abstract::The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years. With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients is affected by ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.7

    authors: Ninan MJ,Morrison VA

    更新日期:2009-04-01 00:00:00